Brown, T. Michelle
Martin, Susan
Fehnel, Sheri E.
Deal, Linda S.
Article History
Received: 3 October 2017
Accepted: 8 March 2018
First Online: 16 March 2018
Ethics approval and consent to participate
: This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki 2008 and reviewed and approved by the RTI International Institutional Review Board. Informed consent was obtained before participation.
: All authors approved this manuscript and provided consent for publication.
: The authors declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This study was conducted by RTI Health Solutions under the direction and funding of Shire Development LLC. RTI Health Solutions was contracted by Shire to design and implement this project. T.M.B., S.M., and S.E.F. are employees of RTI Health Solutions. L.S.D. is currently at Pfizer, Inc. but was employed at Shire Development LLC during the conduct of this project and is currently a shareholder of Shire stock. Shire develops and manufactures treatments for rare diseases, including metachromatic leukodystrophy. The authors have no additional financial relationships or otherwise to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.